Once A Year Osteoporosis Drug Reclast Gets FDA Approval
August 24th, 2007 by 
Barry - Admin BioPharmArena
Swiss drug maker Novartis announced that Reclast (zoledronic acid) has received approval from the US Food and Drug Administration (FDA) as a once a year treatment for women with osteoporosis.
Osteoporosis (literally means “porous bones”) occurs when bone mineral density (BMD) falls and the physical and chemical structure inside bones is disrupted leading to skeletal fragility and bones that fracture easily (it is sometimes called brittle bone disease).
Osteoporosis is caused by a combination of genetic, dietary, lifestyle, hormonal, and age-related factors. It occurs most commonly in postmenopausal women and most treatments are aimed at this group.
Posted in Clinical Research and Clincal Trials | 